nach oben

European Radiology

Erschienen in:

01.10.2010 | Nuclear Medicine

Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas

verfasst von: Michail Plotkin, C. Blechschmidt, G. Auf, F. Nyuyki, L. Geworski, T. Denecke, W. Brenner, F. Stockhammer

Erschienen in: European Radiology | Ausgabe 10/2010

Einloggen, um Zugang zu erhalten

Abstract

Objective:

The management of non-contrast-enhancing brain tumours largely depends on biopsy, which allows a differentiation of low-grade gliomas (LGG) from high-grade gliomas (HGG). The aim of this study was to compare positron emission tomography using 2-[¹⁸F]-fluoro-2-deoxy-d-glucose (FDG-PET) and O-(2-[¹⁸F]-fluoroethyl)-l-tyrosine (FET-PET) in terms of providing target regions for biopsies.

Materials and methods:

Fifteen consecutive patients with newly diagnosed brain tumours (n = 11) or suspected recurrence of a known LGG (n = 4), in whom MRI demonstrated no contrast enhancement, were studied by both FET-PET and FDG-PET. FET-PET, FDG-PET and MRI data were fused, and then transferred to the neurosurgical navigation system, prior to neurosurgical interventions.

Results:

Histology showed HGG (WHO grade III) in 6/15 and LGG (WHO grade II) in 9/15 patients. FET-PET revealed an increased intratumoural tracer uptake in 8/9 LGG and in 5/6 HGG. FDG-PET depicted hypermetabolic spots in 2/9 LGG and in 4/6 HGG. In 6 patients we observed an increased intratumoural uptake of both tracers. In 4 of them, the area of highest FET accumulation in the tumour corresponded to the focus of increased FDG uptake.

Conclusions:

FET-PET appears to be superior to FDG-PET for biopsy planning in non-contrast-enhancing brain tumours. FDG-PET does not provide any additional information in this issue.

Glantz MJ, Burger PC, Herndon JE, Friedman AH, Cairncross JG, Vick NA, Schold SC Jr (1991) Influence of the type of surgery on the histologic diagnosis in patients with anaplastic gliomas. Neurology 41:1741–1744PubMed

Brucher JM (1993) Neuropathological diagnosis with stereotactic biopsies. Possibilities, difficulties and requirements. Acta Neurochir 124:37–39CrossRef

DeAngelis LM (2001) Brain tumors. N Engl J Med 344:114–123CrossRefPubMed

Watanabe M, Tanaka R, Takeda N (1992) Magnetic resonance imaging and histopathology of cerebral gliomas. Neuroradiology 34:463–469CrossRefPubMed

Byrne TN (1994) Imaging of gliomas. Semin Oncol 21:162–171PubMed

Ginsberg LE, Fuller GN, Hashmi M, Leeds NE, Schomer DF (1998) The significance of lack of MR contrast enhancement of supratentorial brain tumors in adults: histopathological evaluation of a series. Surg Neurol 49:436–440CrossRefPubMed

Kondziolka D, Lunsford LD, Martinez AJ (1993) Unreliability of contemporary neurodiagnostic imaging in evaluating suspected adult supratentorial (low-grade) astrocytoma. J Neurosurg 79:533–536CrossRefPubMed

Barker FG 2nd, Chang SM, Huhn SL, Davis RL, Gutin PH, McDermott MW, Wilson CB, Prados MD (1997) Age and the risk of anaplasia in magnetic resonance-nonenhancing supratentorial cerebral tumors. Cancer 80:936–941CrossRefPubMed

Scott JN, Brasher PM, Sevick RJ, Rewcastle NB, Forsyth PA (2002) How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology 59:947–949PubMed

10.

Francavilla TL, Miletich RS, Di Chiro G, Patronas NJ, Rizzoli HV, Wright DC (1989) Positron emission tomography in the detection of malignant degeneration of low-grade gliomas. Neurosurgery 24:1–5CrossRefPubMed

11.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Stanus E, Brotchi J, Hildebrand J (1996) Regional glucose metabolism and histopathology of gliomas. A study based on positron emission tomography-guided stereotactic biopsy. Cancer 78:1098–1106CrossRefPubMed

12.

Herholz K, Pietrzyk U, Voges J, Schroder R, Halber M, Treuer H, Sturm V, Heiss WD (1993) Correlation of glucose consumption and tumor cell density in astrocytomas. A stereotactic PET study. J Neurosurg 79:853–858CrossRefPubMed

13.

Wong TZ, van der Westhuizen GJ, Coleman RE (2002) Positron emission tomography imaging of brain tumors. Neuroimaging Clin N Am 12:615–626CrossRefPubMed

14.

Chung JK, Kim YK, Kim SK, Lee YJ, Paek S, Yeo JS, Jeong JM, Lee DS, Jung HW, Lee MC (2002) Usefulness of ¹¹C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on ¹⁸F-FDG-PET. Eur J Nucl Med Mol Imaging 29:176–182CrossRefPubMed

15.

Delbeke D, Meyerowitz C, Lapidus RL, Maciunas RJ, Jennings MT, Moots PL, Kessler RM (1995) Optimal cutoff levels of F-18 fluorodeoxyglucose uptake in the differentiation of low-grade from high-grade brain tumors with PET. Radiology 195:47–52PubMed

16.

Spence AM, Muzi M, Mankoff DA, O'Sullivan SF, Link JM, Lewellen TK, Lewellen B, Pham P, Minoshima S, Swanson K, Krohn KA (2004) 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. J Nucl Med 45:1653–1659PubMed

17.

Ishizu K, Nishizawa S, Yonekura Y, Sadato N, Magata Y, Tamaki N, Tsuchida T, Okazawa H, Miyatake S, Ishikawa M et al (1994) Effects of hyperglycemia on FDG uptake in human brain and glioma. J Nucl Med 35:1104–1109PubMed

18.

Stockhammer F, Thomale UW, Plotkin M, Hartmann C, von Deimling A (2007) ¹⁸F-fluorodeoxyglucose uptake is associated with 1p and 19q loss in WHO grade II gliomas. J Neurosurg 106:633–637CrossRefPubMed

19.

Levivier M, Massager N, Wikler D, Lorenzoni J, Ruiz S, Devriendt D, David P, Desmedt F, Simon S, Van Houtte P, Brotchi J, Goldman S (2004) Use of stereotactic PET images in dosimetry planning of radiosurgery for brain tumors: clinical experience and proposed classification. J Nucl Med 45:1146–1154PubMed

20.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Lipszyc M, Salmon I, Brotchi J, Levivier M (2004) Combined use of ¹⁸F-fluorodeoxyglucose and ¹¹C-methionine in 45 positron emission tomography-guided stereotactic brain biopsies. J Neurosurg 101:476–483CrossRefPubMed

21.

Goldman S, Levivier M, Pirotte B, Brucher JM, Wikler D, Damhaut P, Dethy S, Brotchi J, Hildebrand J (1997) Regional methionine and glucose uptake in high-grade gliomas: a comparative study on PET-guided stereotactic biopsy. J Nucl Med 38:1459–1462PubMed

22.

Pirotte B, Goldman S, Massager N, David P, Wikler D, Vandesteene A, Salmon I, Brotchi J, Levivier M (2004) Comparison of ¹⁸F-FDG and ¹¹C-methionine for PET-guided stereotactic brain biopsy of gliomas. J Nucl Med 45:1293–1298PubMed

23.

Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller HW, Zilles K, Coenen HH, Langen KJ (2005) O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 128:678–687CrossRefPubMed

24.

Langen KJ, Hamacher K, Weckesser M, Floeth F, Stoffels G, Bauer D, Coenen HH, Pauleit D (2006) O-(2-[18F]fluoroethyl)-L-tyrosine: uptake mechanisms and clinical applications. Nucl Med Biol 33:287–294CrossRefPubMed

25.

Weber W, Wester HJ, Grosu AL, Herz M, Dzewas B, Feldmann HJ, Molls M, Stocklin G, Schwaiger M (2000) O-(2-[18F] fluoroethyl)-L-tyrosine and L-[methyl-11C] methionine uptake in brain tumours: Initial results of a comparative study. Eur J Nucl Med 27:542–549CrossRefPubMed

26.

Pauleit D, Stoffels G, Bachofner A, Floeth FW, Sabel M, Herzog H, Tellmann L, Jansen P, Reifenberger G, Hamacher K, Coenen HH, Langen KJ (2009) Comparison of (18)F-FET and (18)F-FDG PET in brain tumors. Nucl Med Biol 36:779–787CrossRefPubMed

27.

Bjartmarz H, Rehncrona S (2007) Comparison of accuracy and precision between frame- based and frameless stereotactic navigation for deep brain stimulation electrode implantation. Stereotact Funct Neurosurg 85:235–242CrossRefPubMed

28.

McGirt MJ, Villavicencio AT, Bulsara KR, Friedman AH (2003) MRI-guided stereotactic biopsy in the diagnosis of glioma: comparison of biopsy and surgical resection specimen. Surgical neurology 59:277–281, discussion 281-282CrossRefPubMed

29.

Kim JE, Kim DG, Paek SH, Jung HW (2003) Stereotactic biopsy for intracranial lesions: reliability and its impact on the planning of treatment. Acta Neurochir (Wien) 145:547–554, discussion 554-555CrossRef

30.

Muacevic A, Uhl E, Steiger HJ, Reulen HJ (2000) Accuracy and clinical applicability of a passive marker based frameless neuronavigation system. J Clin Neurosci 7:414–418CrossRefPubMed

31.

Messing-Junger AM, Floeth FW, Pauleit D, Reifenberger G, Willing R, Gärtner J, Coenen HH, Langen KJ (2002) Multimodal target point assessment for stereotactic biopsy in children with diffuse bithalamic astrocytomas. Childs Nerv Syst 18:445–449CrossRefPubMed

32.

Floeth FW, Pauleit D, Sabel M, Stoffels G, Reifenberger G, Riemenschneider MJ, Jansen P, Coenen HH, Steiger HJ, Langen KJ (2007) Prognostic value of O-(2-18Ffluoroethyl)-L-tyrosine PET and MRI in low-grade glioma. J Nucl Med 48:519–527CrossRefPubMed

33.

Roessler K, Gatterbauer B, Becherer A, Paul M, Kletter K, Prayer D, Hoeftberger R, Hainfellner J, Asenbaum S, Knosp E (2007) Surgical target selection in cerebral glioma surgery: linking methionine (MET) PET image fusion and neuronavigation. Minim Invasive Neurosurg 50:273–280CrossRefPubMed

34.

Stöber B, Tanase U, Herz M, Seidl C, Schwaiger M, Senekowitsch-Schmidtke R (2006) Differentiation of tumour and inflammation: characterisation of [methyl-3H]methionine (MET) and O-(2-[18F] fluoroethyl)-L-tyrosine (FET) uptake in human tumour and inflammatory cells. Eur J Nucl Med Mol Imaging 33:932–939CrossRefPubMed

35.

Stockhammer F, Plotkin M, Amthauer H, van Landeghem FK, Woiciechowsky C (2008) Correlation of F-18-fluoro-ethyl-tyrosin uptake with vascular and cell density in non-contrast-enhancing gliomas. J Neuro Oncol 88:205–210CrossRef

36.

Hara T, Kondo T, Hara T, Kosaka N (2003) Use of 18F-choline and 11C-choline as contrast agents in positron emission tomography imaging-guided stereotactic biopsy sampling of gliomas. J Neurosurg 99:474–479CrossRefPubMed

37.

Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T (2006) 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 47:904–911PubMed

38.

Beuthien-Baumann B, Bredow J, Burchert W, Füchtner F, Bergmann R, Alheit HD, Reiss G, Hliscs R, Steinmeier R, Franke WG, Johannsen B, Kotzerke J (2003) 3-O-methyl-6-[18F]fluoro-L-DOPA and its evaluation in brain tumour imaging. Eur J Nucl Med Mol Imaging 30:1004–1008CrossRefPubMed

39.

Langen KJ, Jarosch M, Hamacher K, Mühlensiepen H, Weber F, Floeth F, Pauleit D, Herzog H, Coenen HH (2004) Imaging of gliomas with cis-4-[18F]fluoro-L-proline. Nucl Med Biol 31:67–75CrossRefPubMed

40.

Jacobs AH, Thomas A, Kracht LW, Li H, Dittmar C, Garlip G, Galldiks N, Klein JC, Sobesky J, Hilker R, Vollmar S, Herholz K, Wienhard K, Heiss WD (2005) 18F-fluoro-L-thymidine and 11C-methylmethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 46:1948–1958PubMed

41.

Valk PE, Mathis CA, Prados MD, Gilbert JC, Budinger TF (1992) Hypoxia in human gliomas: demonstration by PET with fluorine-18-fluoromisonidazole. J Nucl Med 33:2133–2137PubMed

42.

Hemm S, Rigau V, Chevalier J, Picot MC, Bauchet L, El Fertit H, Rodriguez MA, Cif L, Vayssière N, Zanca M, Baldet P, Segnarbieux F, Coubes P (2005) Stereotactic coregistration of 201Tl SPECT and MRI applied to brain tumor biopsies. J Nucl Med 46:1151–1157PubMed

43.

del Valle M, Torres MD, Gómez Rio M, Rodríguez Fernández A, Sabatel Hernandez G, Ortega Lozano S, Ramos Font C, Bellon Guardia M, López Ramírez E, Llamas Elvira JM (2004) Value of thallium 201-SPECT in typing brain space-occupying lesions. Rev Esp Med Nucl 23:330–337CrossRef

44.

Källén K, Heiling M, Andersson AM, Brun A, Holtås S, Ryding E, Rosén I (1997) Evaluation of malignancy in ring enhancing brain lesions on CT by thallium-201 SPECT. J Neurol Neurosurg Psychiatry 63:569–574CrossRefPubMed

Titel: Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas
verfasst von: Michail Plotkin
C. Blechschmidt
G. Auf
F. Nyuyki
L. Geworski
T. Denecke
W. Brenner
F. Stockhammer
Publikationsdatum: 01.10.2010
Verlag: Springer-Verlag
Erschienen in: European Radiology / Ausgabe 10/2010
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI: https://doi.org/10.1007/s00330-010-1819-2

Neu im Fachgebiet Radiologie

23.04.2024 | Pankreaskarzinom | Nachrichten

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas

Abstract

Objective:

Materials and methods:

Results:

Conclusions:

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie

Springer Medizin

Abstract

Objective:

Materials and methods:

Results:

Conclusions:

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 10/2010

Uterine artery embolisation versus hysterectomy for leiomyomas: primary and 2-year follow-up results of a randomised prospective clinical trial

Elderly patient with acute, left lower abdominal pain: perforated jejunal diverticulitis (2010:7b)

Incremental value of the CT coronary calcium score for the prediction of coronary artery disease

Percutaneous isolated liver perfusion with occlusion balloons and a catheter-based stent-graft-like perfusion device: an experimental study in a porcine model

High-relaxivity contrast-enhanced magnetic resonance neuroimaging: a review

Osteoid osteoma and osteoid osteoma-mimicking lesions: biopsy findings, distinctive MDCT features and treatment by radiofrequency ablation

Neu im Fachgebiet Radiologie

S3-Leitlinie zu Pankreaskrebs aktualisiert

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

Wie toxische Männlichkeit der Gesundheit von Männern schadet

Update Radiologie